Resources
Browse our materials
for additional information

The following is a searchable and filterable list of our news posts, press releases, white papers, articles, scientific posters, and much more.
If you can’t find something, please let us know and we’ll reach out to you as soon as we can.

Filters
Search:
Filter your resources:
  • Daten töten. Den Krebs.

    An article by Friedrich von Bohlen in FOCUS Die Welt in 2023 (in German)
    Download article
  • Molecular Health receives IVDR certification for MH Guide

    Press release, 13 July 2022
    Read more
  • Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions

    Press release, 10 March 2022
    Read more
  • Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports

    Soldatos, T. G. et al. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):540-555. doi: 10.1002/psp4.12765
    Open resource
  • Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics

    Heydt, C. et al. J. Mol. Pathol. 2022, 3(1), 53-67; https://doi.org/10.3390/jmp3010006
    Open resource
  • Discover the benefits of automated variant annotation for your clinical routine

    MH Guide interprets complex genetic data quickly and accurately – for the growing challenges of today and tomorrow
    Read more
  • Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors

    Kim, S. et al. Clin Transl Sci. 2022 Jun;15(6):1430-1438. doi: 10.1111/cts.13254
    Open resource
  • The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease

    Brock, S. et al. Front. Mol. Med. 2022, 2:1035215. https://doi.org/10.3389/fmmed.2022.1035215
    Open resource
  • The earlier, the better – turning data into knowledge

    Predisposition analyses of hereditary cancers
    Read more
  • A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development

    Kim, S. et al. Clin Transl Sci . 2022 Apr;15(4):1003-1013. doi: 10.1111/cts.13219
    Open resource
GDPR Cookie Consent with Real Cookie Banner